This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Coiled-coil domain containing 88A (CCDC88A; GIV); Rho guanine nucleotide exchange factor (GEF; ARHGEF); guanine nucleotide binding protein (G protein), α -inhibiting activity polypeptide 3 (GNAI3; G α i3)	<p>Studies in cell culture suggest that inhibiting the Gαi3-GIV interface could be useful for preventing cancer metastasis associated with GIV expression. In HeLa cells, disruption of GIV-Gαi3 interactions led to lower Akt activation and cell migration, both of which contribute to an oncogenic phenotype, than that seen in controls. Next steps include identifying inhibitors that selectively disrupt the Gαi3-GIV interface.</p> <p>SciBX 2(7); doi:10.1038/scibx.2009.263 Published online Feb. 19, 2009</p>	Patent and licensing status unavailable	<p>Garcia-Marcos, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 9, 2009; doi:10.1073/pnas.0900294106 Contact: Marilyn G. Farquhar, University of California, San Diego, La Jolla, Calif. e-mail: mfarquhar@ucsd.edu</p>